Related Experiment Video
Updated: Mar 9, 2026

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)
Published on: July 3, 2025
Differential modulation of the sGC-cGMP pathway by sGC stimulators and activators in human lung cells
Paula Montero1, María Amparo Bayarri2, Inés Roger3
1Department of Pharmacology, Faculty of Medicine, University of Valencia 46010 Valencia, Spain; Research Foundation of the General University Hospital of Valencia (FIHGUV), 46014 Valencia, Spain; Biomedical Research Networking Centre on Respiratory Diseases (CIBERES), Health Institute Carlos III, 28029 Madrid, Spain.
Abstract:
Chronic lung diseases are characterized by oxidative stress, inflammation, and fibroproliferation, conditions that impair nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic GMP (cGMP) signaling. Here, we investigated the differential effects of an sGC stimulator (riociguat) and an sGC activator (cinaciguat), alone or combined with the PDE5 inhibitor sildenafil, in primary human pulmonary cells exposed to cigarette smoke extract (CSE). Lung tissue from COPD and asthma patients displayed reduced sGC α1 and β1 expression, and CSE induced concentration-dependent oxidation of the sGC heme group, diminishing responsiveness to NO and to riociguat. Cinaciguat, but not riociguat, maintained cGMP production under oxidizing conditions, while co-treatment with sildenafil further increased cGMP levels for both drugs. In epithelial cells, fibroblasts, neutrophils, and endothelial monolayers, cinaciguat and riociguat attenuated CSE-induced oxidative stress, inflammatory cell adhesion, and profibrotic gene expression, with cinaciguat-particularly in combination with sildenafil-showing more robust effects across endpoints. These findings identify distinct pharmacodynamic profiles for sGC stimulators versus activators under oxidative conditions and support sGC modulation as a potential therapeutic approach in oxidative chronic lung diseases.
Insights
Soluble guanylate cyclase (sGC) activators, unlike stimulators, maintain cyclic GMP (cGMP) production under oxidative stress in lung cells. Combining activators with PDE5 inhibitors shows promise for treating chronic lung diseases.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Cell Biology
Background:
- Chronic lung diseases involve oxidative stress, inflammation, and fibrosis, impairing nitric oxide-soluble guanylate cyclase-cyclic GMP (NO-sGC-cGMP) signaling.
- Reduced sGC α1 and β1 expression is observed in COPD and asthma patients.
- Cigarette smoke extract (CSE) causes oxidative damage to sGC, reducing its responsiveness.
Purpose of the Study:
- To investigate the differential effects of an sGC stimulator (riociguat) and an sGC activator (cinaciguat) on pulmonary cells.
- To evaluate the impact of combining these agents with a PDE5 inhibitor (sildenafil).
- To assess their efficacy in mitigating CSE-induced cellular damage and dysfunction.
Main Methods:
- Primary human pulmonary cells (epithelial cells, fibroblasts, neutrophils, endothelial monolayers) were exposed to CSE.
- Cells were treated with riociguat, cinaciguat, sildenafil, or combinations thereof.
- cGMP production, sGC heme oxidation, oxidative stress markers, inflammatory cell adhesion, and profibrotic gene expression were measured.
Main Results:
- CSE oxidized the sGC heme group, diminishing responsiveness to NO and riociguat.
- Cinaciguat, but not riociguat, preserved cGMP production under oxidizing conditions.
- Co-treatment with sildenafil enhanced cGMP levels for both drugs.
- Both drugs attenuated CSE-induced oxidative stress, inflammation, and fibrosis; cinaciguat with sildenafil showed more potent effects.
Conclusions:
- sGC activators exhibit distinct pharmacodynamic profiles compared to stimulators under oxidative conditions.
- Cinaciguat, especially combined with sildenafil, demonstrates robust therapeutic potential.
- sGC modulation represents a promising strategy for treating oxidative chronic lung diseases.
Related Concept Videos
GPCRs Regulate Adenylyl Cylase Activity
Activation and Inactivation of G Proteins
GTPases and their Regulation
Large G-proteins,...
Nitric Oxide Signaling Pathway
Amplifying Signals via Second Messengers
G-Protein Gated Ion Channels
Sensory...

